Formulation Optimization of Scutellarin-loaded HP-β-CD/chitosan Nanoparticles Using Response Surface Methodology with Box-Behnken Design

Overview

Journal Asian J Pharm Sci

Date 2020 Feb 28

PMID 32104349

Citations 15

Authors

Shanshan Liu

Paul C Ho

Affiliations

Soon will be listed here.

Abstract

The aim of this paper is to investigate and optimize the preparation of scutellarin (SCU)-loaded HP-β-CDchitosan (CS) nanoparticles (CD/CS-SCU-NPs). CD/CS-SCU-NPs were prepared by ionic cross-linking method and the process and formulation variables were optimized using response surface methodology (RSM) with a three-level, three factor Box-Behnken design (BBD). The independent variables were the added amounts of CS, sodium tripolyphosphate (TPP) and Pluronic F-68 during the preparation. Dependent variables (responses) were particle size and entrapment efficiency. Mathematical equations and respond surface plots were used to correlate independent and dependent variables. The preparation process and formulation variables were optimized to achieve minimum particle size and maximum entrapment efficiency by calculating the overall desirability value (OD). The optimized NP formulation was characterized for particle size, PDI, zeta potential, entrapment efficiency and drug release. According to the results, an optimized CD/CS-SCU-NP formulation was prepared. Results for particle size, PDI, zeta potential and entrapment efficiency were found to be around 200 nm, 0.5, 25 mV, and 70% respectively. For study, the release of SCU from the NPs exhibited a biphasic release and was in accordance with Higuchi equation. The optimized preparation was simple with the probability for industrialization. The combination use of RSM, BBD and overall desirability values could provide a promising application for incorporating CD into CS nanoparticles as drug delivery carrier and help develop lab-scale procedures.

Citing Articles

Effects of scutellarin on the mechanism of cardiovascular diseases: a review.

Zhang X, Yin T, Wang Y, Du J, Dou J, Zhang X Front Pharmacol. 2024; 14:1329969.

PMID: 38259289 PMC: 10800556. DOI: 10.3389/fphar.2023.1329969.

Design and Evaluation of S-Protected Thiolated-Based Itopride Hydrochloride Polymeric Nanocrystals for Functional Dyspepsia: QbD-Driven Optimization, In Situ, In Vitro, and In Vivo Investigation.

Badr M, Basim P, Hosny K, Rizg W, Naveen N, Kurakula M Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513837 PMC: 10384278. DOI: 10.3390/ph16070925.

The Effect of Chinese Agarwood Essential Oil with Cyclodextrin Inclusion against PCPA-Induced Insomnia Rats.

Lai Y, Hua L, Yang J, Xu J, Chen J, Zhang S Molecules. 2023; 28(2).

PMID: 36677694 PMC: 9864866. DOI: 10.3390/molecules28020635.

Response Surface Methodology (RSM) Powered Formulation Development, Optimization and Evaluation of Thiolated Based Mucoadhesive Nanocrystals for Local Delivery of Simvastatin.

Bakhaidar R, Raghavendra Naveen N, Basim P, Murshid S, Kurakula M, Alamoudi A Polymers (Basel). 2022; 14(23).

PMID: 36501579 PMC: 9737842. DOI: 10.3390/polym14235184.

Optimization of process parameters for fabrication of electrospun nanofibers containing neomycin sulfate and extract for a better diabetic wound healing.

Islam M, Ramesh V, Bhavani P, Goudanavar P, Naveen N, Ramesh B Drug Deliv. 2022; 29(1):3370-3383.

PMID: 36404771 PMC: 9848420. DOI: 10.1080/10717544.2022.2144963.

References

Hao X, Cheng G, Sun J, Zou M, Yu J, Zhang S . Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics. J Pharm Biomed Anal. 2005; 38(2):360-3. DOI: 10.1016/j.jpba.2005.01.004. View

Yang H . Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res. 2010; 27(9):1759-71. PMC: 2933363. DOI: 10.1007/s11095-010-0141-7. View

Hong H, Liu G . Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin. Life Sci. 2004; 74(24):2959-73. DOI: 10.1016/j.lfs.2003.09.074. View

Aljaeid B, Hosny K . Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity. Int J Nanomedicine. 2016; 11:441-7. PMC: 4734792. DOI: 10.2147/IJN.S100625. View

Graff C, Pollack G . Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005; 94(6):1187-95. DOI: 10.1002/jps.20318. View

Li G, Zhong M, Zhou Z, Zhong Y, Ding P, Huang Y . Formulation optimization of chelerythrine loaded O-carboxymethylchitosan microspheres using response surface methodology. Int J Biol Macromol. 2011; 49(5):970-8. DOI: 10.1016/j.ijbiomac.2011.08.019. View

Tiwari G, Tiwari R, Rai A . Cyclodextrins in delivery systems: Applications. J Pharm Bioallied Sci. 2011; 2(2):72-9. PMC: 3147107. DOI: 10.4103/0975-7406.67003. View

Wang Y, Qin F, Tan H, Zhang Y, Jiang M, Lu M . pH-responsive glycol chitosan-cross-linked carboxymethyl-β-cyclodextrin nanoparticles for controlled release of anticancer drugs. Int J Nanomedicine. 2015; 10:7359-69. PMC: 4677651. DOI: 10.2147/IJN.S91906. View

Sinswat P, Tengamnuay P . Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins. Int J Pharm. 2003; 257(1-2):15-22. DOI: 10.1016/s0378-5173(03)00090-5. View

10.

Bahreini E, Aghaiypour K, Abbasalipourkabir R, Mokarram A, Goodarzi M, Saidijam M . Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study. Nanoscale Res Lett. 2014; 9(1):340. PMC: 4110547. DOI: 10.1186/1556-276X-9-340. View

11.

Li Y, Abbaspour M, Grootendorst P, Rauth A, Wu X . Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology. Eur J Pharm Biopharm. 2015; 94:170-9. DOI: 10.1016/j.ejpb.2015.04.028. View

12.

Asasutjarit R, Theerachayanan T, Kewsuwan P, Veeranodha S, Fuongfuchat A, Ritthidej G . Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use. AAPS PharmSciTech. 2015; 16(5):1013-24. PMC: 4674645. DOI: 10.1208/s12249-015-0290-4. View

13.

Abdul Ghafoor Raja M, Katas H, Jing Wen T . Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. PLoS One. 2015; 10(6):e0128963. PMC: 4465927. DOI: 10.1371/journal.pone.0128963. View

14.

Wei Y, Li L, Xi Y, Qian S, Gao Y, Zhang J . Sustained release and enhanced bioavailability of injectable scutellarin-loaded bovine serum albumin nanoparticles. Int J Pharm. 2014; 476(1-2):142-8. DOI: 10.1016/j.ijpharm.2014.09.038. View

15.

Habgood M, Ek J . Delivering drugs into the brain: barriers and possibilities. Ther Deliv. 2012; 1(4):483-8. DOI: 10.4155/tde.10.58. View

16.

Jiang X, Li S, Lan K, Yang J, Zhou J . [Study on the pharmacokinetics of scutellarin in dogs]. Yao Xue Xue Bao. 2003; 38(5):371-3. View

17.

Jingou J, Shilei H, Weiqi L, Danjun W, Tengfei W, Yi X . Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids Surf B Biointerfaces. 2010; 83(1):103-7. DOI: 10.1016/j.colsurfb.2010.11.005. View

18.

Honary S, Ebrahimi P, Hadianamrei R . Optimization of particle size and encapsulation efficiency of vancomycin nanoparticles by response surface methodology. Pharm Dev Technol. 2013; 19(8):987-98. DOI: 10.3109/10837450.2013.846375. View

19.

Zhong D, Yang B, Chen X, Li K, Xu J . Determination of scutellarin in rat plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 796(2):439-44. DOI: 10.1016/j.jchromb.2003.08.002. View

20.

Krauland A, Alonso M . Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int J Pharm. 2007; 340(1-2):134-42. DOI: 10.1016/j.ijpharm.2007.03.005. View